Relapsed/refractory follicular lymphoma carries similar variability in presentation. Therapeutic options include the same regimens traditionally used for first-line therapy; however, they also ...

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate of watch-and-wait patients was not inferior to that o ...

Researchers sought to determine whether mosunetuzumab would have long-term efficacy in patients with follicular lymphoma.

is a population identified as a priority for novel therapy development by the National Clinical Trials Network. POD24 as a factor affecting follicular lymphoma outcomes was first identified by a ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

Despite being declared cancer-free after initial treatment, I grapple with survivor's guilt, questioning why my lymphoma responded to therapy while others did not. When I started receiving treatment ...

CAR T-cell therapy is an effective treatment for aggressive subtypes of follicular lymphoma, according to a clinical trial published in Nature Medicine. A team led by researchers at Weill Cornell ...

stage II-IV and stage I (for patients not willing to or not candidates for radiation); no previous therapy other than radiation for stage I FL, and low–tumor burden. FL with blastoid or large ...